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Abstract
Early randomized controlled trials (RCTs) demonstrated the health benefits of omega-3 fatty acids (n-3), whereas
recent RCTs were negative. We now address the issue, focusing on the temporal changes having occurred: most
patients in recent RCTs are no longer n-3 deficient and the vast majority are now treated with statins. Recent RCTs
testing n-3 against arrhythmias suggest that n-3 reduce the risk only in patients not taking a statin. Other recent
RCTs in secondary prevention were negative although, in a post-hoc analysis separating statin users and non-users,
non-significant protection of n-3 was observed among statin non-users whereas statin users had no effect. Recent
RCTs testing statins - after the implementation of the New Clinical Trial Regulation in 2007 - are negative (or
flawed) suggesting that the lack of effect of n-3 cannot be attributed to a parallel protection by statins. Finally,
statins favor the metabolism of omega-6 fatty acids (n-6), which in turn inhibits n-3 and, contrary to n-3, they
increase insulin resistance and the risk of diabetes. Thus, n-3 and statins are counteractive at several levels and
statins appear to inhibit n-3.
Keywords: omega-3 fatty acids, statins, ischemic heart disease, myocardial infarction, randomized clinical trials, epi-
demiology, mitochondria, insulin resistance, diabetes, n-6 fatty acids
Introduction
Until 2005, studies consistently provided clear evidence
that omega-3 fatty acids (n-3) protect against cardiovas-
cular diseases (CVD) complications [1,2]. They were
thought to reduce the risk of arterial atherosclerotic and
thrombotic obstruction [3,4]; to increase the myocardial
resistance to ischemia-reperfusion injury [5,6]; and to
prevent malignant ventricular arrhythmias [7-9]. Animal
[5-7] and epidemiological studies [8,9] as well as rando-
mized controlled trials (RCTs) [10-13] all supported that
n-3 are protective. This was confirmed in meta-analyses
of both prospective cohort studies and RCTs leading to
the conclusion that an intake of 250 mg/day of marine
n-3 (EPA+DHA (eicosapentanoic acid + docosahexanoic
acid)) reduced fatal CVD by 36% when compared to no
EPA+DHA [14].
Consequently, it was proposed to use blood measure-
ments of n-3 as a predictor of CVD complications. The
omega-3 index - defined as the percentage of EPA+DHA
in blood red cells [15] - reflects the average dietary intake
and the tissue levels of EPA+DHA, including those of the
heart [16,17]. A high omega-3 index (> 8%) is thought to
be associated with a low risk of CVD complications [15]
whereas a low omega-3 index (< 4%) is associated with
increased risk susceptible to be decreased by a preventive
treatment with n-3 (fish oil) supplements. An omega-3
index between 4 and 8% indicates an intermediate risk.
The effects of n-3 supplements are, therefore, expected
to be different in patients with either high or low omega-
3 index with large benefits for those with a low index
(that is, high risk) and small or no benefits for those with
a high index (that is, low risk). This concept is critical
because it suggests that n-3 supplements might be poten-
tially protective against CVD complications only in
patients who are n-3 deficient and not in patients who
are at high risk for reasons other than an n-3 deficiency.
This underlines the fact that n-3 are nutrients and not a
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drug. So far this concept applies only for CVD, not for
other nonvascular and non-cardiac clinical conditions.
Contrary to the expectations, the most recent RCTs -
that is, those published after 2005 - did not confirm the
protective action of n-3 [18-23]. In a recent meta-analysis
examining the efficacy of n-3 supplements (EPA+DHA)
in the secondary prevention of coronary heart disease
(CHD), authors analyzed 13 RCTs involving 20,485
patients with a history of CHD and concluded that n-3
supplements did not consistently reduce CHD mortality,
all-cause mortality and the risk of overall CVD complica-
tions [24]. An explanation could be that the populations
enrolled in the most recent RCTs were different from
those tested in the past RCTs. Indeed, the authors did
not separate early (positive) and recent (negative) RCTs
in their meta-analyses and thereby ignored any temporal
changes in the dietary and blood n-3 status of the
patients enrolled in the early or the recent RCTs. Also, in
subgroup analyses by concomitant medication use, the
authors report a non-significant preventive effect against
the risk of CVD events (relative risk 0.74, 95% confidence
intervals 0.54 to 1.03) among patients not receiving sta-
tins whereas those receiving statins had no protection at
all: relative risk 1.02, 95% confidence intervals 0.92 to
1.12 [24]. These data suggest strong interactions between
n-3 and statins and may at least partly explain the discre-
pancy between recent and early RCTs because the use of
statins has become almost systematic among patients in
recent RCTs, whereas it was rare or even absent in early
RCTs [10-13].
Another puzzling observation is that, contrary to the
results of recent RCTs, recent epidemiological studies
examining associations between n-3 (or fish intake) and
CVD in various populations still demonstrate significant
inverse correlation [1,2,25-29]. This further suggests that
in populations with low use of statins, n-3 remain appar-
ently protective.
How could these findings be explained?
Recent RCTs testing the effects of n-3 fatty acids
Among the most recent n-3 RCTs, there are two main
categories: those testing whether n-3 reduce the risk of
malignant ventricular arrhythmias in patients with an
implantable cardiac defibrillator [18-20], and those test-
ing the effects of n-3 in secondary prevention of CHD
[21-23]. One trial published in 2003 in secondary preven-
tion (DART-2) was not incorporated in the present ana-
lysis because of major design issues [30]. For instance,
the trial was interrupted after one year and then re-
started with a nonconventional re-randomization (which
resulted in different numbers of patients in each of the
four groups), there was no true control group, no placebo
to compare with the fish oil capsules, and finally a total
lack of “blinding” [30]. Another study [31], often cited
because the authors reported an increased risk for ventri-
cular arrhythmias among heart failure patients with the
highest n-3 concentrations in their red blood cells, was
also not incorporated in the present analysis because it is
a very short (one year) and very small observational study
(n = 102) [31].
Thus, in the first category, we have retained three
RCTs.
The first one was published in June 2005 and reported
no significant effect of 1.3 g/day of EPA+DHA [18]. The
omega-3 index of patients receiving EPA+DHA increased
from 4.7 to 8.3% indicating that patients were not n-3 defi-
cient at baseline and were compliant during the follow-up
[18]. About half of the patients in both groups were taking
a statin. Limitations of the trial were the small sample size
(n = 100 per group) and clinical heterogeneity - ischemic
vs. non ischemic heart disease - of the underlying cardiac
diseases. The second trial was published in November
2005 and reported a non-significant effect (28% risk reduc-
tion, P = 0.057 in the intention-to-treat analysis) of 2.6
g/day of EPA+DHA [19]. Interestingly, the effect was sig-
nificant among patients with ischemic heart disease
(hazard ratio 0.70, 95% CI 0.45 to 1.00) and also, no
patient was taking a statin in either group. The omega-3
index increased from 3.4 to 7.6% in the EPA+DHA group
indicating that these patients were slightly n-3 deficient at
baseline and compliant. A major limitation was the short
follow-up (12 months). The third trial was published in
June 2006 and reported no significant effect of 0.96 g/day
of EPA+DHA (20). Only 45% of the patients were taking a
statin. The short follow-up (12 months) was the main lim-
itation of the study. Measurements of plasma EPA indi-
cated that patients were not n-3 deficient at baseline and
were then compliant. There was no protective effect of
EPA+DHA in the primary analysis, but a non-significant
trend toward protection in the EPA+DHA group among
patients with ischemic heart disease: hazard ratio 0.76,
95% CI 0.52 to 1.11 [20].
In summary, these three RCTs do not support a strong
protective effect of EPA+DHA against malignant arrhyth-
mias in patients with an implantable cardiac defibrillator
(ICD). There are, however, several limitations in each trial:
short follow-up, small sample size and medical heteroge-
neity - ischemic vs. non-ischemic heart disease - of the
enrolled patients. Thus, they should be considered indivi-
dually with precaution. In a subsequent meta-analysis
combining the three trials, it was again concluded that
EPA+DHA are not protective [32]. However, the effect
among patients with ischemic heart disease (hazard ratio
0.79, 95% CI 0.60 to 1.06) tended toward protection. It has
to be noted that the pooled sample size remained small
suggesting that the meta-analysis itself was underpowered
to detect protection in patients with ischemic heart dis-
ease. Finally, in a post-hoc analysis combining the two
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trials in which statins were prescribed to some patients
(n = 333), a significant interaction (P < 0.05) was noted
between statins and n-3 suggesting that the association of
statins with n-3 may reduce the benefits of each treatment
[32]. Indeed, in the trial with the most favorable effect of
n-3, no patient was taking a statin [19]. While this interac-
tion, also reported in the meta-analysis discussed above
[24], might be a chance finding, it becomes critical to
address the issue in future studies. Overall then, these
recent RCTs [18-20] suggest that among patients not
severely n-3 deficient at baseline, n-3 supplements may
reduce the risk of malignant arrhythmias, but only among
patients with ischemic heart disease and not taking statins.
This would reach agreement with early RCTs and current
knowledge on n-3 and CVD complications [1-14].
Finally, we note that some recent experimental studies
also did not confirm the anti-arrhythmic effects of n-3
previously reported [7-10] and may even have detected
an arrhythmogenic effect [33,34]. In one study, the main
difference from previous studies using a similar model
of ischemia-induced arrhythmias [7] was that n-3 were
given orally in the form of ethyl esters in the recent stu-
dies [33], instead of through intravenous infusion of
purified n-3 [7]. Whether the dietary administration
itself (vs. infusion) or the use of quite large doses of
ethyl esters (rather than purified n-3) explains these
recent data deserves further investigation. Some other
experimental studies were also confusing and difficult to
interpret. For instance, the same group of investigators
published, the same year 2007, data showing either pro-
motion of arrhythmias by n-3 in isolated pig hearts [34]
or reduction of the incidence of arrhythmias by n-3 in
pig ventricular myocytes [35].
In any case, compared with previous human studies, a
new RCT testing n-3 supplements would require a larger
sample size, longer follow-up and selection of patients
with ischemic heart disease - with and without statins -
and a low omega-3 index at baseline. As a lab to lab varia-
bility in n-3 measurements may confuse the data, these
measurements should be done in a unique central lab. As
the probability of such a RCT is very low, a careful analysis
of the recent RCTs in secondary prevention of CHD is
mandatory.
Regarding this second category of trials - RCTs testing
n-3 in secondary prevention of CHD - one should con-
sider two periods: before and after the systematic use of
statins in secondary prevention of CHD. During the pre-
statin period, the mid-1980s to the end of 1990s, two large
trials (DART and GISSI), reported significant benefits of
marine n-3 in survivors of a recent myocardial infarction
[10,11]. On the basis of these two trials, and also of the
results of the Lyon Diet Heart Study (in which patients
were supplemented with the plant n-3 alpha-linolenic
acid, the precursor of EPA and DHA in the endogenous
pathway [36,37], leading to a significant increase in EPA),
n-3 were claimed to reduce the risk of CHD complications
and mortality in secondary prevention [14]. Importantly,
few patients were taking statins and their average intake of
n-3 was low. These three trials had a large media coverage
and the idea that plant and marine n-3 are critical for the
prevention of CHD spread rapidly to the medical commu-
nity and the public. In 2002, the American Heart Associa-
tion recommended two fatty fish meals per week for the
general population and 1 g EPA+DHA per day for patients
with CHD [38]. As a consequence, during the next period,
after the year 2000 approximately, the vast majority of
CHD patients, in addition to taking statins, were aware of
the importance of having more n-3 in their diet leading
many survivors of a heart attack to take an n-3 supple-
ment. Thus, the conditions in which n-3 supplements
were tested in secondary prevention in this second period
[21-23] were very different from those of the first one
[10-13].
If we only consider RCTs reporting ‘hard’ (myocardial
infarction and cardiac death) endpoints, with sample size
and follow-up large enough to analyze mortality, three
RCTs should be examined.
In a first RCT (Sufolom3), 2,501 CHD patients were ran-
domized to receive either 0.6 g/day of EPA+DHA or
placebo and were followed up for 4.7 years [21]. About
85% of patients were taking a statin. Baseline plasma n-3
levels were high, indicating that most patients were not n-
3 deficient. For instance, plasma EPA at baseline (1.20% of
total fatty acids) was higher than the level measured in the
experimental group of the Lyon Trial (1.03 ± 0.06 vs. 0.76
± 0.05% in the control group) receiving n-3 supplementa-
tion [12,13]. In Sufolom3, allocation to n-3 was not asso-
ciated with any significant benefit. A limitation of the trial
was the low complication rate (1.3% per year) compared,
for instance, with 4.9% in the Lyon trial.
In a second RCT (Omega), 3,851 survivors of a recent
myocardial infarction were given 0.84 g/day of EPA
+DHA (compared with a placebo) [22]. About 95% of the
patients were taking a statin and the consumption of n-3
was rather high as only 3% of patients were not eating
fish and about half of the patients were eating fish several
times a week. There was no significant difference
between the patients receiving n-3 and those taking the
placebo [22]. A major limitation of the trial was the short
follow-up (one year).
In a third trial (Alpha Omega), 4,837 patients who had a
myocardial infarction were randomized to receive for
40 months one of four margarines: a margarine supple-
mented with EPA+DHA, a margarine supplemented with
ALA, a margarine supplemented with EPA+DHA+ALA
and a placebo margarine [23]. On average, patients con-
sumed 19 g of margarine per day, which resulted in addi-
tional daily intakes of 380 mg EPA+DHA, 1.9 g ALA or
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both in the active-treatment groups. About 86% of
patients were taking a statin and average consumption of
fish at baseline was 15 g/day in each subgroup corre-
sponding to an average intake of EPA+DHA of about 125
mg/day, which was confirmed by measuring blood n-3.
Treatment with n-3 did not reduce the risk in the primary
analysis whereas some benefits, in subgroup analyses,
could be seen in women and diabetics [23].
In a subsequent analysis, the Alpha Omega investigators
explored the interactions between statins and n-3 with the
hypothesis that statins may have reduced the protective
effects of n-3 [39]. They analyzed separately statin users
and non-users. Among statin users, 13% developed CVD
complications against 15% among non-users and n-3 sup-
plementation did not reduce complications among statin
users. However, among statin non-users, only 9% of those
receiving n-3 developed CVD complications compared
with 18% in the placebo group (hazard ratio 0.46, 95% CI
0.21 to 1.01). The authors conclude that statins reduced
the effects of n-3 fatty acids [39]. But contrary to their
hypothesis stating that the absence of benefits of n-3
resulted from a dilution effect - no additional benefit of n-
3 could be seen in patients strongly protected by statins -
it might also be hypothesized that statins inhibit n-3
because the lowest risk was indeed seen among statin
non-users taking n-3.
Two other trials [40,41] combining n-3 fatty acids and
statins may provide useful information regarding the inter-
actions between n-3 and statins in patients with established
ischemic heart disease (secondary prevention).
The first one, named JELIS (for the Japan EPA Lipid
Intervention Study), is a very large open-label trial pub-
lished in 2007 that tested the effect of 1.8 g/day of EPA
associated with a statin in patients with or without (74%
of the cohort) ischemic heart disease [40]. The control
group was receiving a statin only (no placebo). The
authors report a significant effect of EPA on the primary
endpoint. In a secondary analysis, among the patients
with ischemic heart disease (n = 4,848), 197 events
occurred in the control group after a mean follow-up of
4.6 years against 158 in the EPA group (hazard ratio
0.81, 95% CI 0.66 to 1.00). This non-significant differ-
ence between the two groups was not confirmed when
only comparing the hard endpoints (cardiac death and
nonfatal myocardial infarction) in the two groups. In
fact, there were major design issues in this trial (the trial
was neither double-blinded nor placebo-controlled) and
it is prudent to conclude that high dose EPA had no sig-
nificant effect in secondary prevention in JELIS [40].
Whether the lack of significant effect resulted from the
high consumption of marine n-3 from fish, as expected
in these Japanese patients, or from the use of statins or
both is not clear.
Finally, the GISSI-HF trial was published in 2008 and
reported the effect of 1 g EPA+DHA in patients with
chronic heart failure [41]. Most of these patients had
mild heart failure (63% were in stage II of the New York
Heart Association) and 50% of them had established
ischemic heart disease with various degrees of post-
infarction left ventricular dysfunction [41]. Thus, about
50% were in the context of secondary prevention of CHD
very similar to the patients enrolled in three of the trials
discussed above [21-23]. It was, however, a complex pro-
tocol with a first randomization, among 7,046 eligible
patients, to receive either n-3 or a placebo, and a second
randomization among 4,631 of the same cohort to
receive either a statin (rosuvastatin) or a placebo. As 778
patients in the n-3 group were receiving a statin before
entering the study, 801 in the placebo group, the effect of
n-3 was evaluated in 3,098 statin users compared with
3,121 statin users receiving a placebo instead of n-3.
There were, therefore, four subgroups in that trial
with one single group receiving only placebos. The
investigators published two articles reporting separately
the effects of either n-3 [41] or rosuvastatin [42], and
ignoring the interactions between the two treatments.
The striking and surprising results of these two com-
bined trials were that neither rosuvastatin nor n-3 were
protective [41,42]. In GISSI-HF testing n-3, there was a
non-significant trend toward protection (9% reduction
of mortality, log-rank test P = 0.12) but no effect when
comparing ischemic complications (fatal and nonfatal
myocardial infarction and stroke) with 204 and 208 end-
points in the n-3 and placebo groups, respectively [41].
Strikingly, there was no protection in GISSI-HF testing
rosuvastatin [42]. Thus, whatever the endpoints, recur-
rent infarction, ventricular arrhythmias or recurrent epi-
sode of heart failure, no significant protection was
observed with either n-3 or rosuvastatin [41,42]. These
data were particularly surprising regarding rosuvastatin
as, in agreement with the prevalent theory stating that
“the higher the risk, the higher the benefits of choles-
terol-lowering”, these patients should have been pro-
tected, in particular those (50% of the cohort) who were
in secondary prevention of CHD with various degrees of
post-infarct left ventricular dysfunction.
On the basis of GISSI-HF testing either rosuvastatin or
n-3, it could be stated that the interactions between rosu-
vastatin and n-3 resulted in reciprocal inhibition of the
statin by n-3 and of n-3 by the statin. However, a similar
lack of protection by the statin was confirmed in another
trial [43] in which rosuvastatin was tested against placebo
(in the absence of n-3) in survivors of a previous myocar-
dial infarction with various degrees of myocardial dys-
function and various symptoms of chronic heart failure.
Rosuvastatin was proven again to not be protective [43],
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including in patients with mild symptoms (stage II of the
New York Heart Association Classification) of heart fail-
ure, indicating that the lack of effect of the statin in
GISSI-HF was not due to any inhibition by n-3. More-
over, it is no longer possible to argue that the absence of
benefits of n-3 was due to the striking protection offered
by the statin since rosuvastatin was proven to not be pro-
tective [42,43].
The two next questions are then whether there are any
known biological mechanisms by which statins could
inhibit the effects of n-3, thereby supporting the theory
that statins inhibit n-3, and why recent RCTs testing sta-
tins were negative.
Mechanisms through which statins may inhibit n-3
Several mechanisms have been identified.
It has been shown, including in an RCT in CHD patients
[44], that statins increase arachidonic acid, the main n-6
fatty acid in cell membranes [44,45]. This may in turn
inhibit the protective effects of n-3 because n-6 and n-3
fatty acids are in competition through various pathways
involved in the development and complications of CHD
[3,5,6,12,13,46-48]. Although this view is still discussed
[49], n-3 are clearly more protective when n-6 are low
[12,13,50] and n-6 might even be deleterious when given
in large amounts and in the absence of n-3 [51,52]. Thus
statins may inhibit n-3 by interfering in the n-3/n-6 inter-
play and favoring n-6.
A second mechanism would be through alteration of
mitochondrial function, a key component of myocardial
preconditioning [53-55]. Chronic myocardial precondi-
tioning, that is, the ability of the myocardium to withstand
an ischemia-reperfusion injury and limit the extent of cell
death during and after myocardial ischemia [5,6,53,54], is
a major determinant of the outcome of any heart attack.
Mitochondria are critical in the induction of myocardial
preconditioning [55], and also of neuroprotection [56],
and n-3 induce a chronic myocardial preconditioning state
[5,6] which is likely explained by “improved” mitochon-
drial function [57-59]. On the other hand, statins are toxic
for the mitochondria in a dose-dependent manner [60-62]
and patients treated with statins do have impairment of
mitochondrial respiration [63]. In animal experiments,
coenzyme Q10, a key component in mitochondrial bioe-
nergy transfer and the synthesis of which is inhibited by
statins [61], was reduced in case of impaired heart mito-
chondrial function [61]. Also, in statin-treated dogs, lower
coenzyme Q10 was associated with deficits in a task that
measures executive function, an equivalent of cognitive
function in humans [64,65]. Endogenous production of
coenzyme Q10 is inhibited by blocking the HMG-CoA
reductase enzyme with statins [61,65] and decreased
plasma coenzyme Q10 was confirmed in statin-treated
CHD patients included in a RCT [66]. Thus, whereas the
precise point of interaction between statins and n-3 and
the dose-effect interactions remain to be fully identified, it
is clear that n-3 and statins are counteractive at the mito-
chondria level.
In line with the mitochondria issue discussed above, a
growing body of evidence demonstrates a link between
disturbances in mitochondrial functioning, insulin resis-
tance and diabetes [67-70]. In particular, mitochondrial
function is required for appropriate glucose-induced insu-
lin secretion [67,68]. In addition, statins provoke myalgias
[71], often exacerbated by exercise, resulting in reduced
physical activity which in turn increases insulin resistance
and the risk of type 2 diabetes [72,73]. It is, therefore, not
unexpected that statins increase both insulin resistance
[74] and the risk of new-onset type 2 diabetes [75-78]. The
real incidence and severity of that complication, which
increases the risks of fatal diseases, such as cancers, infec-
tious diseases, stroke and myocardial infarction [79], are
still unknown. Data extracted from commercial RCTs and
post-hoc analyses, including meta-analyses of selected
RCTs [76-78], do not help to clarify the issue. More con-
vincing data are expected from long-term cohort studies,
and one recent study in post-menopausal women reported
that statins increased the risk of new-onset diabetes by
about 60% [75], which is considerable and needs confirma-
tion. Whether the supposed benefits of statins exceed the
diabetes hazard needs careful and independent analysis
(see below).
In contrast, n-3, from either plant or marine sources,
decrease insulin resistance and the risk of diabetes
[80-84]. They interact with the n-3 fatty acid receptor/
sensor GPR120 [85], whose dysfunction results in insulin
resistance and obesity in both rodents and humans [86].
The use of objective biomarkers of n-3 consumption con-
firmed the (inverse) associations between n-3 and dia-
betes [87], although confounders may obscure these
associations; in particular, the geographic location of the
studied populations [88]. This probably reflects the type
of fish consumed by the populations, their actual content
in EPA+DHA and the presence of environmental con-
taminants [89]. Actually, exposure to persistent organic
pollutants results in mitochondrial dysfunction and
increased insulin resistance in both animal and humans
[89-92]. Thus, statins and organic pollutants may inhibit
the protective effects of n-3 against insulin resistance and
diabetes by similarly altering mitochondrial function.
These interactions between statins and n-3 may explain
why statins decrease memory [93] and energy and also
increase fatigue with exertion [94] since n-3 are major
lipids of the brain and nervous system.
Finally, such a negative action on the central nervous
system probably explains the confusing data regarding the
effects of n-3 in the prevention of cognitive decline
because the main negative studies were conducted in
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patients taking statins [95], whereas the vast majority of
the patients in the positive studies were statin non-users
[96].
In summary, statins can inhibit the protective effects of
n-3 through several established biological mechanisms.
Why have recent RCTs testing statins been negative?
For some authors statin therapy is the cornerstone of the
primary and secondary prevention of CVD [97-100],
sometimes even claiming, concerning cholesterol, that
“lower is better and physiologically normal” [101], which is
controversial. Other experts say that there are very good
reasons to “abandon LDL-cholesterol targets” [102]. In
view of the weak efficiency of statins in many groups of
patients, in terms of absolute risk reduction, for instance
in primary prevention [103] and in women [104-107], and
because of their (considerably under-estimated) deleter-
ious side-effects [60-65,71,74-78,93,94,108-110], many
physicians and experts conclude that it is time to reassess
the benefits and risks of statin therapy. Obviously, overes-
timating clinical benefits or underestimating toxic side-
effects is of major importance to public health [111]. And,
indeed, studies can be limited by conflicts of interest and
results should be interpreted with caution. As an example,
most statin RCTs do not report any difference between
the placebo and statin groups regarding skeletal muscle
toxicity, whereas post-marketing surveillance indicates
that at least 15% of statin users do have muscle weakness
or pain [112], a side-effect which is dose-dependent and
associated with strong impact on quality of life [113]. This
clearly indicates that results of commercial RCTs should
be taken with precaution.
The discovery that statins inhibit the protection pro-
vided by n-3 may be an additional argument for those
who think that the use of statins should be restricted.
Should then, for example, statins be limited to specific
clinical conditions associated with a high absolute CVD
risk, such as secondary prevention of CHD, as proposed
by certain cardiologists [114]?
Whether the effects of statins are different in secondary
and in primary prevention remains a confusing and critical
issue in cardiology. Many physicians still think that statins
are protective in secondary but not in primary prevention
[114]. However, myocardial infarction or stroke in primary
prevention results from the same pathological process as
infarction (or a stroke) in secondary prevention. The only
difference is not the pathophysiology but the level of likeli-
hood in the tested populations: in patients with a prior
infarction, the risk is obviously higher than in healthy peo-
ple without a previous heart attack. The mechanism
(thrombotic obstruction, among other possible mechan-
isms) is the same but, given the very different probability
of observing such complications in the two populations,
the sample size and duration of follow-up (required to test
any hypothesis in a RCT) should be adapted. In brief, we
need thousands of healthy people to demonstrate the
antithrombotic effect of any treatment but only hundreds
of survivors of infarction. The same reasoning applies for
the effects of statins and their hypothetic anti-obstructive
effect. Thus, if statins are not protective in primary pre-
vention, there is no scientific or medical reason to believe
that they are protective in secondary prevention; and it is
exactly what we have seen in recent RCTs in both primary
and secondary prevention. The best illustration of that are
the four RCTs testing rosuvastatin. It is noteworthy that
these four placebo-controlled trials were published after
the implementation of the new Clinical Trial Regulations
[42,43,115,116]. This is a critical issue because investiga-
tors and sponsors were then aware that they were under
careful surveillance (contrary to the past) and that they
had to comply with a complex and demanding set of legal,
ethical and regulatory requirements, contravention of
which may lead to criminal proceedings [117,118].
The story should be briefly recalled. Since the Vioxx
debacle [119,120] and the implementation of the new Clin-
ical Trial Regulations and the Good Clinical Practice Direc-
tive 2005/28/EC [117,118], there have been fundamental
changes in the conduct and reports of RCTs. Inspections
by health authorities now concern study sites, laboratories,
sponsors and contract research organizations. Clearly, the
prevalence of bias, spin and misreporting in RCTs has sig-
nificantly decreased [121-124] although confusion and con-
troversies still exist regarding the quality of many studies,
as well as the safety and real benefits of many marketed
products [125-130]. And indeed, since the implementation
of the new Clinical Trial Regulations [117,118], all the
RCTs testing the effects of statins in patients at high risk of
CVD and expected to get large benefits of cholesterol-low-
ering, (patients with post-infarct left ventricular dysfunc-
tion [42,43], chronic kidney failure [115,131] or diabetes
[131-133]) were either negative or sometimes obviously
flawed or misinterpreted [116,133-137]. These striking
temporal changes in the efficiency of statins tested in
RCTs, before and after the implementation of the new
Clinical Trials Regulations and improvement of surveil-
lance by the Health Authorities and politicians
[42,43,115,131-137], not only raised puzzling questions
about the use of statins in high-risk patients but also ques-
tion the validity of the many positive commercial RCTs
published before the new Regulations came into force, that
is, before 2006-2007 [133,136,137].
Let us consider the four placebo-controlled trials test-
ing rosuvastatin. They were conducted in patients with
post-infarct left ventricular dysfunction [42,43], chronic
kidney failure [11] and in primary prevention [116].
Regarding the first two RCTs, CORONA and GISSI-HF
[42,43] already discussed above with the RCTs testing
n-3, some experts argue that the failure of rosuvastatin
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to reduce the risk in these specific patients was not sur-
prising because almost no CVD complications or deaths
were expected to fall into the category that statins could
prevent, for example, myocardial ischemia or infarction
and stroke. Actually, as shown in Table 2 in the COR-
ONA article [43], this view is totally wrong, as 588 and
554 ischemic coronary events were recorded in the two
groups in CORONA. In addition, 283 and 272 cardiac
deaths occurred in ischemic coronary events against
only 191 and 193 deaths due to worsening heart failure,
a type of death not expected to be prevented by the sta-
tin [43]. In other words and in accordance with the cho-
lesterol-statin theory, the risk of most of these ischemic
events should have been reduced by the statin treat-
ment. Thus, unexpectedly the statin failed in CORONA
[43] despite striking reduction of cholesterol levels as
well as the inflammatory marker CRP!
In fact, the large numbers of ischemic complications in
CORONA were not unexpected - neither the sponsors
nor the investigators were naive enough to launch a very
expensive trial without the hope that rosuvastatin will be
effective - because 100% of the recruited patients were sur-
vivors of a previous myocardial infarction and thus
expected to be at high risk of recurrence, the best situation
in theory to prescribe a statin and demonstrate its effec-
tiveness. The fact that they also had various degrees of
post-infarction left ventricular dysfunction and some
symptoms of chronic heart failure does not change the
problem, as perfectly understood by the sponsor when
launching the trial. As a matter of fact, when looking at
the effects of rosuvastatin in function of the severity of the
symptoms of chronic heart failure, there was again no dif-
ference between the groups: those with mild heart failure
(NYHA class II) symptoms also had no reduction of the
primary endpoint: 219 vs. 217 events in the placebo group.
GISSI-HF, another RCT testing rosuvastatin, is a little bit
different because only 50% of the patients were survivors of
a previous infarction and, thus, in secondary prevention
[42]. However, regarding the occurrence (or recurrence) of
ischemic events (myocardial infarction and stroke), the
same trends were observed in GISSI-HF as in CORONA,
with a total lack of effect of the statin regarding the
ischemic events expected to be prevented by the statin [42].
CORONA and GISSI-HF, the first trials testing statins in
secondary prevention since the implementation of the New
Clinical Trial Regulation, proved to be negative despite a
striking reduction of cholesterol (and of the inflammatory
marker CRP), thus raising one major question: did the past
“positive” trials - published before the implementation of
the New Clinical Trial Regulation, with statins in secondary
prevention conform to the present scientific standards? As
discussed below about the landmark 4S trial (as an exam-
ple) in secondary prevention [138], this is very doubtful.
The third RCT testing rosuvastatin against placebo was
the AURORA trial in patients with chronic kidney failure
[115]. More than 50% of the patients had some cardio-
vascular diseases as seen in Table 1 in the AURORA arti-
cle, in addition to their kidney problem, and were,
therefore, also in secondary prevention. However, despite
striking reduction of cholesterol and CRP, rosuvastatin
failed to show any protection; which is in agreement with
the results of another RCT (testing atorvastatin this time)
and in similar chronic kidney failure patients mixing pri-
mary and secondary prevention [131].
The next obvious question is: if the statins are not
effective in these high-risk patients (secondary preven-
tion) why would physicians expect them to be efficient in
low-risk patients (primary prevention)? This is a critical
public health issue and the last rosuvastatin RCT may
help answer the question.
Actually, the fourth placebo-controlled RCT testing
rosuvastatin was JUPITER in primary prevention [116].
There have been many critiques regarding JUPITER
[136,139-141] because of trial design and conduct issues.
Among them, it is noteworthy that there have been over
the years several versions of the cardiovascular mortality
endpoint, the major endpoint in cardiovascular epide-
miology, the versions provided by the sponsor to the
FDA [142,143] being different from those published in
medical journals [116,144,145]. This indicates a weak and
confusing clinical endpoint adjudication process. Still
more puzzling, we note that two different versions of the
overall mortality curves were published by the JUPITER
investigators. In the first version in 2008, the Kaplan-
Meier curves were converging [116] - indeed noted by
the FDA statisticians as a critical issue to interpret the
effects of rosuvastatin on mortality [142] - whereas in the
second version published in 2009, the curves were consis-
tently and sustainably diverging [145]. Whether these
variations in clinical endpoints and survival curves repre-
sent misreporting or a flaw is not the point of this article.
However, it makes the JUPITER results at least doubtful
and not consistent [136,139-145].
In any case, it is now apparent that experts indepen-
dent from the sponsor should have a look at the raw
(hospital) data of each patient, including those who do
not have any complication during the trial, before validat-
ing (freezing) the dataset and starting the statistical ana-
lysis. Only one version of the clinical results should exist
and the statisticians should be totally independent from
the sponsor and totally free of any conflict of interest.
External audit should be an obligation to re-introduce
confidence regarding the validity of the datasets of com-
mercial trials.
In that context, what should we think about JUPITER
and the different versions of cardiovascular mortality?
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Apparently, (we were unable to find any secondary
review of JUPITER endpoint by the FDA officers), the
Endocrine-Metabolic Division of FDA never challenged
or disputed any data the sponsor presented on JUPITER.
FDA officers simply accepted the sponsor’s JUPITER
data as 100% true and without any mistake; although the
sole existence of several different versions of cardiovascu-
lar mortality should have motivated an independent audit
of the raw data obtained in each site.
To summarize, the overall clinical data regarding rosu-
vastatin, (three totally negative RCTs in high-risk patients
mainly in secondary prevention [42,43,115] and one
highly questionable trial in primary prevention [116]),
suggest that the implementation of the New Clinical
Trial Regulations had a major negative impact on the
efficiency of statins to reduce the risk of CVD complica-
tions. As the only statin tested in these new regulatory
conditions was rosuvastatin, the next question is whether
other statins would have been as efficient as they have
been reported to be if they were tested in the same regu-
latory conditions as rosuvastatin. The answer is likely in
the recent SATURN trial in which two intensive statin
regimens, one of them being rosuvastatin (40 mg daily)
and the other one atorvastatin (80 mg daily), were com-
pared [146]; there was no between-group difference in
the numbers of CVD complications recorded during this
short trial (52 and 49 events) as well as for the surrogate
ultrasound endpoint [146]. This total absence of differ-
ence between the two statins in SATURN actually sug-
gests that, after the implementation of the New Clinical
Trial Regulations, the (lack of) effect of atorvastatin par-
allels the (lack of) effect of rosuvastatin. This is not unex-
pected given the parallel total absence of effects of both
atorvastatin and rosuvastatin in patients with chronic
kidney disease as discussed above [115,131].
This raises major questions regarding the possibility of
summarizing and encompassing the totality of the data
about statins. Incorporating in the same meta-analysis
RCTs published before and after the implementation of
the New Clinical Trial Regulations [99,103-106,133,135,
147,148] is highly questionable, in particular when non-
randomized subgroup (and questionable) data are
included into the analysis [99,103-106,133,135,147,148].
In the same way, it could be said that meta-analyses
incorporating flawed RCTs and/or not incorporating
unpublished and “unknown” RCTs suffer major publica-
tion bias and are of low scientific and medical value. It is
well established that industry-sponsored RCTs are more
likely than non-industry-sponsored trials to report favor-
able results for drug treatment because of biased reporting,
biased interpretation, or both [149]. Also, investigators of
the RCTs testing the statins, and reported between 1994
and 2004, were rarely independent from the sponsors and,
in some landmark RCTs, such as 4S [138], MIRACL [150]
and CARDS [151] (and also in the recent JUPITER trial
[116]), the sponsor employees themselves were actually
conducting the study on the field or even in charge of the
data analysis [138,150]. This is even more problematic
than a presumed lack of independence of the investigators
from the sponsors and is today, and should have been,
unacceptable. Investigators must be totally and unequivo-
cally independent from the sponsors to be credible. In the
4S and MIRACL studies, for instance, the only statistician
of the studies was an employee of the sponsor, which
raises major concerns regarding the validity of the results
of 4S [138,150] as any sponsor’s employee would inevitably
favor the product of his employer.
The ultimate and critical question therefore is: should
we take seriously the results of RCTs reported before the
implementation of the New Clinical Trials Regulations?
In the same way, what is the scientific value of the many
meta-analyses [76-78,97,99,103-106,135,147,148] pooling
data from commercial RCTs published before and after
the New Clinical Trial Regulations? The obvious contra-
diction between the results of past and recent RCTs test-
ing the statins is a major public health issue as the primary
explanation is that the past RCTs were not conducted in
agreement with the new Clinical Trials Regulations and
that their results were probably not scientifically valid.
The same reasoning should apply to meta-analyses
summarizing the cardiovascular effects of n-3 supple-
ments by pooling data of past and recent RCTs [24,152].
Conclusions
In patients taking a statin, n-3 supplements are not effec-
tive against CVD complications, including studies in
which statins had no effect. This excludes a dilution
effect, that is, a lack of additional benefits of n-3 in
patients already protected by statins, and suggests that
statins actually inhibit n-3.
Although confirmation is needed, such a negative inter-
action would have major clinical implications while likely
explaining, at least partly, the negative results of the most
recent RCTs testing n-3 supplements in high-risk
patients [18-24]. An additional, not alternative, explana-
tion is that, in contrast with the past trials involving
high-risk n-3 deficient patients [10-13], most patients
enrolled in recent RCTs were not severely n-3 deficient
[18-23]. The risk related to the omega-3 index was, there-
fore, not high in these patients [18-23] and, in turn, the
expected benefits of n-3 supplementation were not high,
which may explain that statins could have almost totally
eliminated the small benefits expected from n-3 supple-
ments in these specific patients. It is, therefore, not sur-
prising that in the recent ORIGIN trial testing the effects
of about 900 mg of EPA+DHA in patients with dysglyce-
mia no benefit was observed [153]. In ORIGIN, more
than 50% of the patients were taking a statin, the median
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intake of EPA+DHA was higher than 200 mg/day, indi-
cating that the overall intake of n-3 was not low and that
the patients were not n-3 deficient, and the absolute risk
of CVD complications (< 3 per 100 patients-year) was
low [153].
Thus, in agreement with the omega-3 index concept, n-
3 supplements would be protective only in patients who
are more or less n-3 deficient and not in patients who are
at high risk for reasons other than n-3 deficiency.
In other words, n-3 are indispensable nutrients, which
means that it is dangerous to be n-3 deficient, which is not
rare in many populations [1,2,14], and not drugs suscepti-
ble to reducing the overall risk of CVD complications
independent of the n-3 status of the persons studied.
As discussed in the Introduction section, this view
does not include clinical conditions other than CVD.
For instance, the right dosage of n-3, in the absence of
statins, for the prevention of cognitive decline and
dementia might be much higher than the current
recommended dietary intake to prevent CVD [14,38].
Further studies are needed to answer this question. The
design (and results) of future RCTs testing n-3 supple-
ment should take that issue into consideration.
In conclusion, the present analysis raises several major
questions regarding the optimal strategy to prevent the
development and complications of CVD.
Given the weak (or lack of) efficiency of statins in
recent RCTs and their major toxic side-effects, including
inhibition of n-3, what should physicians do?
The priority is to adopt a healthy lifestyle, which is the
critical strategy to be actually protected [12,13,54,72,
73,84,92,154,155]. Should physicians continue to pre-
scribe statins?
Because of the many insidious side-effects of statins
and the lack of independent recent data confirming the
benefits of statins in both primary and secondary pre-
vention [136,137], we actually need a new and indepen-
dent re-evaluation of the benefit/risk ratio of statins.
In contrast, and given the almost total innocuousness of
n-3 in most populations, n-3 supplements should be given
without restriction to any patient potentially n-3 deficient
and systematically in all patients with established n-3 defi-
ciency. This will give time to change the dietary habits -
the alternative solution to correct any degree of n-3
deficiency [12-14,38,54,80-84] - of these patients at high
risk of fatal CVD complications because of n-3 deficiency.
Definitely, it is time to rethink the use of n-3 supple-
ments and statins (and other cholesterol-lowering drugs)
for the prevention of CVD complications. Only scientists
and physicians free of conflicts of interest and indepen-
dent from the pharmaceutical industry, both the n-3 sup-
plement and statin industries, should be invited to review
the whole story from the beginning.
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